Stock Market

Teva Biosimilar Prolia Approval Breakthrough

By Bullbit Editorial · March 30, 2026

• WhatTeva gains approval for Amgen's Prolia biosimilar
• WhyThis approval expands treatment options for patients
• SignalStrong demand for affordable alternatives expected
• TargetTeva aims to capture market share with new product
• RiskCompetition from existing biosimilars remains a challenge

More breaking news →